EP3583091B1 - Composés de dispositifs optiquement actifs - Google Patents
Composés de dispositifs optiquement actifs Download PDFInfo
- Publication number
- EP3583091B1 EP3583091B1 EP18703798.1A EP18703798A EP3583091B1 EP 3583091 B1 EP3583091 B1 EP 3583091B1 EP 18703798 A EP18703798 A EP 18703798A EP 3583091 B1 EP3583091 B1 EP 3583091B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- atoms
- formula
- chcf
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 119
- 230000002209 hydrophobic effect Effects 0.000 title description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 100
- 125000000217 alkyl group Chemical group 0.000 claims description 67
- 229920000642 polymer Polymers 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 46
- -1 acryl Chemical group 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 37
- 125000005647 linker group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 230000003287 optical effect Effects 0.000 claims description 8
- 239000007943 implant Substances 0.000 claims description 7
- 125000004001 thioalkyl group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 5
- 125000005369 trialkoxysilyl group Chemical group 0.000 claims description 5
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 393
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 210
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 206
- 239000000243 solution Substances 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000000178 monomer Substances 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- 239000000376 reactant Substances 0.000 description 25
- 0 Cc1c(*)nc(C)nc1* Chemical compound Cc1c(*)nc(C)nc1* 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 125000001424 substituent group Chemical group 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 16
- 238000006116 polymerization reaction Methods 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 10
- 150000002009 diols Chemical class 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 239000003999 initiator Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 150000002989 phenols Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 208000002177 Cataract Diseases 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- 239000004971 Cross linker Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 7
- 239000004926 polymethyl methacrylate Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 6
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical compound CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000005886 esterification reaction Methods 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- RKJXFOUCVXKGDE-UHFFFAOYSA-N 1-methyl-2-phenylindol-6-ol Chemical compound OC1=CC=C2C=C(N(C2=C1)C)C1=CC=CC=C1 RKJXFOUCVXKGDE-UHFFFAOYSA-N 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 239000006096 absorbing agent Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000003505 polymerization initiator Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 5
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
- FTALTLPZDVFJSS-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl prop-2-enoate Chemical compound CCOCCOCCOC(=O)C=C FTALTLPZDVFJSS-UHFFFAOYSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- NYXRBVDWXOWLSC-UHFFFAOYSA-N O-(4-formyl-3-methoxyphenyl) N,N-dimethylcarbamothioate Chemical compound C(=O)C1=C(C=C(C=C1)OC(N(C)C)=S)OC NYXRBVDWXOWLSC-UHFFFAOYSA-N 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 description 4
- 239000004809 Teflon Substances 0.000 description 4
- 229920006362 Teflon® Polymers 0.000 description 4
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 4
- 229960001701 chloroform Drugs 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000009477 glass transition Effects 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 4
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- PBKONEOXTCPAFI-UHFFFAOYSA-N 1,2,4-trichlorobenzene Chemical compound ClC1=CC=C(Cl)C(Cl)=C1 PBKONEOXTCPAFI-UHFFFAOYSA-N 0.000 description 3
- MARQNYITQHCUPM-UHFFFAOYSA-N 2-phenyl-1-benzofuran-6-ol Chemical compound O1C2=CC(O)=CC=C2C=C1C1=CC=CC=C1 MARQNYITQHCUPM-UHFFFAOYSA-N 0.000 description 3
- BTCAHHDEULKYID-UHFFFAOYSA-N 2-phenyl-1-benzothiophen-6-ol Chemical compound S1C2=CC(O)=CC=C2C=C1C1=CC=CC=C1 BTCAHHDEULKYID-UHFFFAOYSA-N 0.000 description 3
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 3
- MYTAJZGSFLZCPS-UHFFFAOYSA-N 5-methoxy-2-(2-phenylethynyl)aniline Chemical compound NC1=CC(OC)=CC=C1C#CC1=CC=CC=C1 MYTAJZGSFLZCPS-UHFFFAOYSA-N 0.000 description 3
- HLGUWWKXVOYVFR-UHFFFAOYSA-N 6-methoxy-2-phenyl-1-benzothiophene Chemical compound S1C2=CC(OC)=CC=C2C=C1C1=CC=CC=C1 HLGUWWKXVOYVFR-UHFFFAOYSA-N 0.000 description 3
- JLVHJFKZSFKVHO-UHFFFAOYSA-N 6-methoxy-2-phenyl-1h-indole Chemical compound N1C2=CC(OC)=CC=C2C=C1C1=CC=CC=C1 JLVHJFKZSFKVHO-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000006959 Williamson synthesis reaction Methods 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000005661 deetherification reaction Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 3
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- MUTLSSXILNEYGN-UHFFFAOYSA-N (2,2,3,3,4,4-hexafluoro-5-hydroxypentyl) prop-2-enoate Chemical compound C(C=C)(=O)OCC(C(C(CO)(F)F)(F)F)(F)F MUTLSSXILNEYGN-UHFFFAOYSA-N 0.000 description 2
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 2
- VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 description 2
- NLFWMDSVHPNXJA-UHFFFAOYSA-N 16-hydroxyhexadecyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCCCCCCCCCO NLFWMDSVHPNXJA-UHFFFAOYSA-N 0.000 description 2
- YHUMWODYFPVRTP-UHFFFAOYSA-N 16-hydroxyhexadecyl prop-2-enoate Chemical compound OCCCCCCCCCCCCCCCCOC(=O)C=C YHUMWODYFPVRTP-UHFFFAOYSA-N 0.000 description 2
- HZDCCHQSZMIRHG-UHFFFAOYSA-N 18-hydroxyoctadecyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCCCCCCCCCCCO HZDCCHQSZMIRHG-UHFFFAOYSA-N 0.000 description 2
- JHGWYTWADRWKPW-UHFFFAOYSA-N 18-hydroxyoctadecyl prop-2-enoate Chemical compound OCCCCCCCCCCCCCCCCCCOC(=O)C=C JHGWYTWADRWKPW-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- QDHQSSYFWKTCNH-UHFFFAOYSA-N 2-(2-ethyl-4-pentylphenyl)-1-benzofuran-6-thiol Chemical compound C(C)C1=C(C=CC(=C1)CCCCC)C=1OC2=C(C=1)C=CC(=C2)S QDHQSSYFWKTCNH-UHFFFAOYSA-N 0.000 description 2
- XWWZPHOYYQGQIX-UHFFFAOYSA-N 2-(4-bromophenyl)-6-methoxy-1-benzothiophene Chemical compound S1C2=CC(OC)=CC=C2C=C1C1=CC=C(Br)C=C1 XWWZPHOYYQGQIX-UHFFFAOYSA-N 0.000 description 2
- WZUODJNEIXSNEU-UHFFFAOYSA-N 2-Hydroxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(O)=C1 WZUODJNEIXSNEU-UHFFFAOYSA-N 0.000 description 2
- KQFLZVJZJOQLNC-UHFFFAOYSA-N 2-[4-pentyl-2-(trifluoromethoxy)phenyl]-1-benzofuran-6-thiol Chemical compound C(CCCC)C1=CC(=C(C=C1)C=1OC2=C(C=1)C=CC(=C2)S)OC(F)(F)F KQFLZVJZJOQLNC-UHFFFAOYSA-N 0.000 description 2
- RZVINYQDSSQUKO-UHFFFAOYSA-N 2-phenoxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC1=CC=CC=C1 RZVINYQDSSQUKO-UHFFFAOYSA-N 0.000 description 2
- HXMZLDUBSSPQIB-UHFFFAOYSA-N 2-phenyl-1-benzofuran Chemical class O1C2=CC=CC=C2C=C1C1=CC=CC=C1 HXMZLDUBSSPQIB-UHFFFAOYSA-N 0.000 description 2
- QMAQLCVJIYANPZ-UHFFFAOYSA-N 2-propoxyethyl acetate Chemical compound CCCOCCOC(C)=O QMAQLCVJIYANPZ-UHFFFAOYSA-N 0.000 description 2
- WESJBCJEZBGYIZ-UHFFFAOYSA-N 4-methoxy-2-sulfanylbenzaldehyde Chemical compound COC1=CC=C(C=O)C(S)=C1 WESJBCJEZBGYIZ-UHFFFAOYSA-N 0.000 description 2
- SBXDHFCIEVASHU-UHFFFAOYSA-N 6-methoxy-1-methyl-2-phenylindole Chemical compound CN1C2=CC(OC)=CC=C2C=C1C1=CC=CC=C1 SBXDHFCIEVASHU-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CEBUTFSGTQUZMU-UHFFFAOYSA-N O-(4-formyl-3-hydroxyphenyl) N,N-dimethylcarbamothioate Chemical compound C(=O)C1=C(C=C(C=C1)OC(N(C)C)=S)O CEBUTFSGTQUZMU-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000006668 aldol addition reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 229930006711 bornane-2,3-dione Natural products 0.000 description 2
- 125000005620 boronic acid group Chemical class 0.000 description 2
- 238000012662 bulk polymerization Methods 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- VLNBQUAHERCLKT-UHFFFAOYSA-N dimethylamino benzoate Chemical group CN(C)OC(=O)C1=CC=CC=C1 VLNBQUAHERCLKT-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- 125000005641 methacryl group Chemical group 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- MJKFDRJNRQQSDA-UHFFFAOYSA-N methyl 2-bromo-2-(4-bromophenyl)acetate Chemical compound COC(=O)C(Br)C1=CC=C(Br)C=C1 MJKFDRJNRQQSDA-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- CSVRUJBOWHSVMA-UHFFFAOYSA-N oxolan-2-yl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC1CCCO1 CSVRUJBOWHSVMA-UHFFFAOYSA-N 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- ABWPXVJNCQKYDR-UHFFFAOYSA-N pentylboronic acid Chemical compound CCCCCB(O)O ABWPXVJNCQKYDR-UHFFFAOYSA-N 0.000 description 2
- 125000002081 peroxide group Chemical group 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007870 radical polymerization initiator Substances 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 229940102001 zinc bromide Drugs 0.000 description 2
- PVCVRLMCLUQGBT-UHFFFAOYSA-N (1-tert-butylcyclohexyl) (1-tert-butylcyclohexyl)oxycarbonyloxy carbonate Chemical compound C1CCCCC1(C(C)(C)C)OC(=O)OOC(=O)OC1(C(C)(C)C)CCCCC1 PVCVRLMCLUQGBT-UHFFFAOYSA-N 0.000 description 1
- FMQPBWHSNCRVQJ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C(F)(F)F)C(F)(F)F FMQPBWHSNCRVQJ-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- QTKPMCIBUROOGY-UHFFFAOYSA-N 2,2,2-trifluoroethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(F)(F)F QTKPMCIBUROOGY-UHFFFAOYSA-N 0.000 description 1
- CLISWDZSTWQFNX-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(F)(F)C(F)(F)F CLISWDZSTWQFNX-UHFFFAOYSA-N 0.000 description 1
- VIEHKBXCWMMOOU-UHFFFAOYSA-N 2,2,3,3,4,4,4-heptafluorobutyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(F)(F)C(F)(F)C(F)(F)F VIEHKBXCWMMOOU-UHFFFAOYSA-N 0.000 description 1
- YRZBLQVLPLBEME-UHFFFAOYSA-N 2-(2-ethyl-4-pentylphenyl)-6-methoxy-1-benzofuran Chemical compound C(C)C1=C(C=CC(=C1)CCCCC)C=1OC2=C(C=1)C=CC(=C2)OC YRZBLQVLPLBEME-UHFFFAOYSA-N 0.000 description 1
- UHUNBTZEYQJRQR-UHFFFAOYSA-N 2-(4-bromophenyl)-6-methoxy-1-benzofuran Chemical compound BrC1=CC=C(C=C1)C=1OC2=C(C=1)C=CC(=C2)OC UHUNBTZEYQJRQR-UHFFFAOYSA-N 0.000 description 1
- MZHBJMCGUSCOJN-UHFFFAOYSA-N 2-[(2-cyanocyclohexyl)diazenyl]cyclohexane-1-carbonitrile Chemical compound N#CC1CCCCC1N=NC1C(C#N)CCCC1 MZHBJMCGUSCOJN-UHFFFAOYSA-N 0.000 description 1
- CYDBBGSUZRDOPE-UHFFFAOYSA-N 2-iodo-5-methoxyaniline Chemical compound COC1=CC=C(I)C(N)=C1 CYDBBGSUZRDOPE-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- LBMHPHUSGIEGHJ-UHFFFAOYSA-N 2-phenyl-1-benzothiophene Chemical class S1C2=CC=CC=C2C=C1C1=CC=CC=C1 LBMHPHUSGIEGHJ-UHFFFAOYSA-N 0.000 description 1
- KRRZGDVYMTWLCG-UHFFFAOYSA-N 3,3,4,4,5,5,6,6-octafluoro-8-[[2-[4-pentyl-2-(trifluoromethoxy)phenyl]-1-benzofuran-6-yl]sulfanyl]octan-1-ol Chemical compound FC(CCO)(C(C(C(CCSC1=CC2=C(C=C(O2)C2=C(C=C(C=C2)CCCCC)OC(F)(F)F)C=C1)(F)F)(F)F)(F)F)F KRRZGDVYMTWLCG-UHFFFAOYSA-N 0.000 description 1
- HVAPLSNCVYXFDQ-UHFFFAOYSA-N 3,3-dimethyl-1-(trifluoromethyl)-1$l^{3},2-benziodoxole Chemical compound C1=CC=C2C(C)(C)OI(C(F)(F)F)C2=C1 HVAPLSNCVYXFDQ-UHFFFAOYSA-N 0.000 description 1
- GRIWJVSWLJHHEM-UHFFFAOYSA-N 3-hydroxy-2-methoxybenzaldehyde Chemical compound COC1=C(O)C=CC=C1C=O GRIWJVSWLJHHEM-UHFFFAOYSA-N 0.000 description 1
- HWDSXZLYIKESML-UHFFFAOYSA-N 3-phenylchromen-2-one Chemical compound O=C1OC=2C=CC=CC=2C=C1C1=CC=CC=C1 HWDSXZLYIKESML-UHFFFAOYSA-N 0.000 description 1
- HWAVMMXGJWRAAV-UHFFFAOYSA-N 6-methoxy-2-(4-pentylphenyl)-1-benzofuran Chemical compound COC1=CC2=C(C=C(O2)C2=CC=C(C=C2)CCCCC)C=C1 HWAVMMXGJWRAAV-UHFFFAOYSA-N 0.000 description 1
- LYLAXKHZQMHOCP-UHFFFAOYSA-N 6-methoxy-2-(4-pentylphenyl)-1-benzothiophene Chemical compound COC=1C=CC2=C(SC(=C2)C2=CC=C(C=C2)CCCCC)C=1 LYLAXKHZQMHOCP-UHFFFAOYSA-N 0.000 description 1
- QTQAUQBONUHAOC-UHFFFAOYSA-N 6-methoxy-2-phenyl-1-benzofuran Chemical compound O1C2=CC(OC)=CC=C2C=C1C1=CC=CC=C1 QTQAUQBONUHAOC-UHFFFAOYSA-N 0.000 description 1
- FMSVUUWEWUZTGB-UHFFFAOYSA-N 8-bromo-3,3,4,4,5,5,6,6-octafluorooctan-1-ol Chemical compound BrCCC(C(C(C(CCO)(F)F)(F)F)(F)F)(F)F FMSVUUWEWUZTGB-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- VBSALKOZQJECNP-UHFFFAOYSA-N C=CC(OCC(CC(F)(F)F)COc1cc([s]c(-c2ccccc2)c2)c2cc1)=O Chemical compound C=CC(OCC(CC(F)(F)F)COc1cc([s]c(-c2ccccc2)c2)c2cc1)=O VBSALKOZQJECNP-UHFFFAOYSA-N 0.000 description 1
- JPNVAIKOVFJCSD-UHFFFAOYSA-N C=CC(OCC(OC(OC(OC(CSc1ccc(cc(-c2ccccc2)[o]2)c2c1)(F)F)(F)F)(F)F)(F)F)=O Chemical compound C=CC(OCC(OC(OC(OC(CSc1ccc(cc(-c2ccccc2)[o]2)c2c1)(F)F)(F)F)(F)F)(F)F)=O JPNVAIKOVFJCSD-UHFFFAOYSA-N 0.000 description 1
- XTZKULOTOKVNSS-UHFFFAOYSA-N CC(C(C(C)C1(F)F)C(F)(F)F)C1(F)F Chemical compound CC(C(C(C)C1(F)F)C(F)(F)F)C1(F)F XTZKULOTOKVNSS-UHFFFAOYSA-N 0.000 description 1
- XJOZIVDJSXLVQA-UHFFFAOYSA-N CC(C(C)(C(C)C1(F)F)C(F)(F)F)C1(F)F Chemical compound CC(C(C)(C(C)C1(F)F)C(F)(F)F)C1(F)F XJOZIVDJSXLVQA-UHFFFAOYSA-N 0.000 description 1
- QFSIKAMSNYHWOZ-UHFFFAOYSA-N CC(CCC1C)C1(C)C(F)(F)F Chemical compound CC(CCC1C)C1(C)C(F)(F)F QFSIKAMSNYHWOZ-UHFFFAOYSA-N 0.000 description 1
- WAMIAXNFKNZXGJ-UHFFFAOYSA-N CC(CCC1C)C1C(F)(F)F Chemical compound CC(CCC1C)C1C(F)(F)F WAMIAXNFKNZXGJ-UHFFFAOYSA-N 0.000 description 1
- SSBMDQNLDCHUBU-UHFFFAOYSA-N CCCCCc(cc1)cc(C(F)(F)F)c1-c([n](C)c1c2)cc1ccc2OCCC(C(C(C(CCOC(C=C)=O)(F)F)(F)F)(F)F)(F)F Chemical compound CCCCCc(cc1)cc(C(F)(F)F)c1-c([n](C)c1c2)cc1ccc2OCCC(C(C(C(CCOC(C=C)=O)(F)F)(F)F)(F)F)(F)F SSBMDQNLDCHUBU-UHFFFAOYSA-N 0.000 description 1
- VXTQXCSICJGIHF-UHFFFAOYSA-N CCCCCc(cc1)cc(CC)c1-c([n](C)c1c2)cc1ccc2OCCC(C(C(C(CCOC(C(C)=C)=O)(F)F)(F)F)(F)F)(F)F Chemical compound CCCCCc(cc1)cc(CC)c1-c([n](C)c1c2)cc1ccc2OCCC(C(C(C(CCOC(C(C)=C)=O)(F)F)(F)F)(F)F)(F)F VXTQXCSICJGIHF-UHFFFAOYSA-N 0.000 description 1
- DMBNSHPZSBXLLO-UHFFFAOYSA-N CCCCCc(cc1)cc(CC)c1-c([n](CC)c1c2)cc1ccc2OCCC(C(C(C(CCOC(C=C)=O)(F)F)(F)F)(F)F)(F)F Chemical compound CCCCCc(cc1)cc(CC)c1-c([n](CC)c1c2)cc1ccc2OCCC(C(C(C(CCOC(C=C)=O)(F)F)(F)F)(F)F)(F)F DMBNSHPZSBXLLO-UHFFFAOYSA-N 0.000 description 1
- FCRCIIJAKOAPFC-UHFFFAOYSA-N CCCCCc(cc1)cc(OC(F)(F)F)c1-c([o]c1c2)cc1ccc2OCC(OC(OC(OC(COC(C(C)(C)C(C)(CC(C)(C)N)N)=O)(F)F)(F)F)(F)F)(F)F Chemical compound CCCCCc(cc1)cc(OC(F)(F)F)c1-c([o]c1c2)cc1ccc2OCC(OC(OC(OC(COC(C(C)(C)C(C)(CC(C)(C)N)N)=O)(F)F)(F)F)(F)F)(F)F FCRCIIJAKOAPFC-UHFFFAOYSA-N 0.000 description 1
- FMTGMPCLMZKQGD-UHFFFAOYSA-N CCCCCc(cc1)cc(OC(F)(F)F)c1-c([o]c1c2)cc1ccc2OCC(OC(OC(O[F]C(COC(C(C)(C)C(CC(C)(C)N)N)=O)F)(F)F)(F)F)(F)F Chemical compound CCCCCc(cc1)cc(OC(F)(F)F)c1-c([o]c1c2)cc1ccc2OCC(OC(OC(O[F]C(COC(C(C)(C)C(CC(C)(C)N)N)=O)F)(F)F)(F)F)(F)F FMTGMPCLMZKQGD-UHFFFAOYSA-N 0.000 description 1
- LNCLQNUXMRWCME-UHFFFAOYSA-N CCCCCc(cc1)cc(OC(F)(F)F)c1-c([o]c1c2)cc1ccc2SCC(OC(OC(OC(COC(C(C)=C)=O)(F)F)(F)F)(F)F)(F)F Chemical compound CCCCCc(cc1)cc(OC(F)(F)F)c1-c([o]c1c2)cc1ccc2SCC(OC(OC(OC(COC(C(C)=C)=O)(F)F)(F)F)(F)F)(F)F LNCLQNUXMRWCME-UHFFFAOYSA-N 0.000 description 1
- QWVZRQHXYGPAMQ-UHFFFAOYSA-N CCCCCc(cc1)cc(OC)c1-c([o]c1c2)cc1ccc2OCC(OC(OC(OC(COC(C(C)(C)C(C)(CC(C)(C)N)N)=O)(F)F)(F)F)(F)F)(F)F Chemical compound CCCCCc(cc1)cc(OC)c1-c([o]c1c2)cc1ccc2OCC(OC(OC(OC(COC(C(C)(C)C(C)(CC(C)(C)N)N)=O)(F)F)(F)F)(F)F)(F)F QWVZRQHXYGPAMQ-UHFFFAOYSA-N 0.000 description 1
- YZGHOKHXVWGMQZ-UHFFFAOYSA-N CCCCCc(cc1)cc(OC)c1-c([o]c1c2)cc1ccc2OCC(OC(OC([O](C(COC(C(C)(C)C(CC(C)(C)N)N)=O)F)F)(F)F)(F)F)(F)F Chemical compound CCCCCc(cc1)cc(OC)c1-c([o]c1c2)cc1ccc2OCC(OC(OC([O](C(COC(C(C)(C)C(CC(C)(C)N)N)=O)F)F)(F)F)(F)F)(F)F YZGHOKHXVWGMQZ-UHFFFAOYSA-N 0.000 description 1
- YARZQPYUXZGHFK-UHFFFAOYSA-N CCCCCc1ccc(-c([o]c2c3)cc2ccc3OC)c(OC(F)(F)F)c1 Chemical compound CCCCCc1ccc(-c([o]c2c3)cc2ccc3OC)c(OC(F)(F)F)c1 YARZQPYUXZGHFK-UHFFFAOYSA-N 0.000 description 1
- DNAHYHKSEGPENF-UHFFFAOYSA-N CCCCCc1ccc(-c([s]c2c3)cc2ccc3OCCCC(CCCOC(C=C)=O)(F)F)c(CC)c1 Chemical compound CCCCCc1ccc(-c([s]c2c3)cc2ccc3OCCCC(CCCOC(C=C)=O)(F)F)c(CC)c1 DNAHYHKSEGPENF-UHFFFAOYSA-N 0.000 description 1
- LPGUYJWHPWJVFT-UHFFFAOYSA-N CCCCc(cc1)cc(OC)c1-c([s]c1c2)cc1ccc2OCCC(OC(OC(CCOC(C=C)=O)(F)F)(F)F)(F)F Chemical compound CCCCc(cc1)cc(OC)c1-c([s]c1c2)cc1ccc2OCCC(OC(OC(CCOC(C=C)=O)(F)F)(F)F)(F)F LPGUYJWHPWJVFT-UHFFFAOYSA-N 0.000 description 1
- XIKZLAMGLYAMPG-UHFFFAOYSA-N CCOC(C(C)(C(F)(F)F)C(OCC)=O)=O Chemical compound CCOC(C(C)(C(F)(F)F)C(OCC)=O)=O XIKZLAMGLYAMPG-UHFFFAOYSA-N 0.000 description 1
- WYWJFCIXZOHXPF-UHFFFAOYSA-N CC[n](c(-c1ccccc1)c1)c2c1ccc(OCCCC(CCCO)(F)F)c2 Chemical compound CC[n](c(-c1ccccc1)c1)c2c1ccc(OCCCC(CCCO)(F)F)c2 WYWJFCIXZOHXPF-UHFFFAOYSA-N 0.000 description 1
- OZZVGALUHMLDFC-UHFFFAOYSA-N CCc(cc(C(F)(F)F)cc1)c1-c([o]c1c2)cc1ccc2OC Chemical compound CCc(cc(C(F)(F)F)cc1)c1-c([o]c1c2)cc1ccc2OC OZZVGALUHMLDFC-UHFFFAOYSA-N 0.000 description 1
- GPXXHLCPPMUUDJ-UHFFFAOYSA-N CCc(cc1)ccc1-c1cc(ccc(OCCC(C(C(C(CCOC(C(C)=C)=O)(F)F)(F)F)(F)F)(F)F)c2)c2[n]1C(C)C Chemical compound CCc(cc1)ccc1-c1cc(ccc(OCCC(C(C(C(CCOC(C(C)=C)=O)(F)F)(F)F)(F)F)(F)F)c2)c2[n]1C(C)C GPXXHLCPPMUUDJ-UHFFFAOYSA-N 0.000 description 1
- HTZMBUVMGPWJJC-UHFFFAOYSA-N CCc(cccc1)c1-c([o]c1c2)cc1ccc2O Chemical compound CCc(cccc1)c1-c([o]c1c2)cc1ccc2O HTZMBUVMGPWJJC-UHFFFAOYSA-N 0.000 description 1
- GMZBBUUBFRPHBU-UHFFFAOYSA-N CCc1c(C(C(OC)=O)Br)ccc(Br)c1 Chemical compound CCc1c(C(C(OC)=O)Br)ccc(Br)c1 GMZBBUUBFRPHBU-UHFFFAOYSA-N 0.000 description 1
- UUFNOSVGIZRBIQ-UHFFFAOYSA-N CCc1ccccc1-c([n](CC(C)C)c1c2)cc1ccc2OCCC(C(C(C(CCOC(C=C)=O)(F)F)(F)F)(F)F)(F)F Chemical compound CCc1ccccc1-c([n](CC(C)C)c1c2)cc1ccc2OCCC(C(C(C(CCOC(C=C)=O)(F)F)(F)F)(F)F)(F)F UUFNOSVGIZRBIQ-UHFFFAOYSA-N 0.000 description 1
- MIELJBHTUMNYGU-UHFFFAOYSA-N CCc1ccccc1C(C(OC)=O)Br Chemical compound CCc1ccccc1C(C(OC)=O)Br MIELJBHTUMNYGU-UHFFFAOYSA-N 0.000 description 1
- FXIIMAAGAYOQOA-UHFFFAOYSA-N CCc1ccccc1CC(OC)=O Chemical compound CCc1ccccc1CC(OC)=O FXIIMAAGAYOQOA-UHFFFAOYSA-N 0.000 description 1
- MIAAIRSKCZUAIH-UHFFFAOYSA-N COC(C(c(ccc(Br)c1)c1OC(F)(F)F)Br)=O Chemical compound COC(C(c(ccc(Br)c1)c1OC(F)(F)F)Br)=O MIAAIRSKCZUAIH-UHFFFAOYSA-N 0.000 description 1
- BNQRSYFOIRGRKV-UHFFFAOYSA-N COC(Cc1ccccc1OC)=O Chemical compound COC(Cc1ccccc1OC)=O BNQRSYFOIRGRKV-UHFFFAOYSA-N 0.000 description 1
- BFCAAAQAWFZCER-UHFFFAOYSA-N COc1cc([s]c(-c2cccnc2)c2)c2cc1 Chemical compound COc1cc([s]c(-c2cccnc2)c2)c2cc1 BFCAAAQAWFZCER-UHFFFAOYSA-N 0.000 description 1
- 101100448444 Caenorhabditis elegans gsp-3 gene Proteins 0.000 description 1
- 101100448445 Caenorhabditis elegans gsp-4 gene Proteins 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 101150092780 GSP1 gene Proteins 0.000 description 1
- 101150035751 GSP2 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical class COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- QERSJUQDOFURTP-UHFFFAOYSA-N O-[3-[4-chloro-2-(trifluoromethyl)phenyl]-2-oxochromen-7-yl] N,N-dimethylcarbamothioate Chemical compound ClC1=CC(=C(C=C1)C=1C(OC2=CC(=CC=C2C=1)OC(N(C)C)=S)=O)C(F)(F)F QERSJUQDOFURTP-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- LZRGHWBCXWEYJQ-UHFFFAOYSA-N S-(4-formyl-3-hydroxyphenyl) N,N-dimethylcarbamothioate Chemical class CN(C(SC1=CC(=C(C=C1)C=O)O)=O)C LZRGHWBCXWEYJQ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- SSSQEFVQPGGYOQ-UHFFFAOYSA-N bis(trifluoromethylsulfonyl)azanide;phenyl(2,2,2-trifluoroethyl)iodanium Chemical compound FC(F)(F)C[I+]C1=CC=CC=C1.FC(F)(F)S(=O)(=O)[N-]S(=O)(=O)C(F)(F)F SSSQEFVQPGGYOQ-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- UPQZOUHVTJNGFK-UHFFFAOYSA-N diethyl 2-methylpropanedioate Chemical compound CCOC(=O)C(C)C(=O)OCC UPQZOUHVTJNGFK-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- AMVCFIFDMKEIRE-UHFFFAOYSA-N methyl 2-(2-bromophenyl)acetate Chemical compound COC(=O)CC1=CC=CC=C1Br AMVCFIFDMKEIRE-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PHWISQNXPLXQRU-UHFFFAOYSA-N n,n-dimethylcarbamothioyl chloride Chemical compound CN(C)C(Cl)=S PHWISQNXPLXQRU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- WRAQQYDMVSCOTE-UHFFFAOYSA-N phenyl prop-2-enoate Chemical group C=CC(=O)OC1=CC=CC=C1 WRAQQYDMVSCOTE-UHFFFAOYSA-N 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001709 polysilazane Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical class OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000012719 thermal polymerization Methods 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- OFHCXWMZXQBQMH-UHFFFAOYSA-N trifluoro(trifluoromethylsulfanyl)methane Chemical compound FC(F)(F)SC(F)(F)F OFHCXWMZXQBQMH-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- QXXHXTRTGZBOGD-UHFFFAOYSA-M trifluoromethanesulfonate;5-(trifluoromethyl)dibenzothiophen-5-ium Chemical compound [O-]S(=O)(=O)C(F)(F)F.C1=CC=C2[S+](C(F)(F)F)C3=CC=CC=C3C2=C1 QXXHXTRTGZBOGD-UHFFFAOYSA-M 0.000 description 1
- PZJJKWKADRNWSW-UHFFFAOYSA-N trimethoxysilicon Chemical group CO[Si](OC)OC PZJJKWKADRNWSW-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/16—Intraocular lenses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/04—Homopolymers or copolymers of esters
- C08L33/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
Definitions
- the present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
- Cataract is a general term for an affection of the eye that leads to a loss of vision and in the extreme to blindness by clouding of the normally clear lens of the eye. It is the major cause of blindness in the world, affecting more than 100 million people. Due to the fact that its major cause is age and the population's average age is increasing, it is expected that the number of cataracts will continue to increase substantially in the future.
- Intraocular lens Effective treatment of cataract is only possible by surgical intervention, whereby the natural lens of the eye is removed through an incision in the cornea and replaced with an artificial lens, often also referred to as "intraocular lens".
- intraocular lens an artificial lens
- current state-of-the-art surgical methods employ eye mapping so as to approximate the refractive power best suited to the respective patient.
- cataract surgery is one of the most widely used and safest surgical procedures it is not without specific post-surgery problems.
- the refractive power of the implanted intraocular lens (IOL) is insufficient for restoring good vision.
- Such problems may, for example, be caused by changes in eye geometry as consequence of the surgery as well as irregular wound healing and positioning errors that result in the artificial lens not having the optimal optical properties.
- the patient will still require corrective vision aids, e.g. glasses, to be able to see correctly.
- the resulting refractive power of the implanted artificial lens is so far removed from the required refractive power that further surgery will be required. Particularly for aged persons this is not desirable because the body's capability for healing is reduced with increasing age.
- there is the risk of attracting endophthalmitis, an inflammation of the eye which can even lead to a complete loss of vision or worse, loss of the eye.
- WO 2016/200401 A1 describes liquid crystal materials having photoalignment properties.
- Teflon AF® Poly(methyl methacrylate) intraocular lenses (IOLs) that were coated with Teflon AF®, an amorphous, transparent, and highly hydrophobic fluorocarbon polymer is known from Jean-Marc technikis, J Cataract Refract Surg. 1998, 24, 371-379 .
- Teflon AF® (Dupont de Nemours) is a poly(tetra-fluoroethylene co-hexafluoro-propyl-2 cyclodethoxydifluoroethylene). Constituted entirely of high-energy bonds, it is stable at temperatures up to 260°C and chemically very resistant. The refractive index is 1.32.
- PMMA IOL model 808A, Kabi Pharmacia Production B.V.
- C 8 F 18 fluorocarbon solvent
- the compounds disclosed therein suffer from being too stiff and too brittle so that they can't be rolled or folded and are thus not fit to be implanted by state of the art cataract surgical methods, particularly by state of the art micro-incision cataract surgical methods.
- the invention relates to compounds of formula (I) wherein
- the invention relates further to compositions comprising at least one of said compounds of formula (I) and/or their polymerized forms as well as to articles comprising at least one polymerized compound of formula (I).
- the invention relates to a process for forming such article, said process comprising the steps of
- the invention relates to a process for changing the optical properties of an article according to the invention, said process comprising the steps of
- the compounds of formula (I) and all preferred embodiments of compounds of formula (I) according to the present invention include all stereoisomers or racemic mixtures.
- compounds according to the invention are more stable toward UV-irradiation due to lower absorption range. Furthermore the chemical and hydrolytical stability is higher and given due to their intrinsic chemical nature e.g. due to lack of positions prone to nucleophilic attacks, like sp 2 centers and the absence of cyclic lactone structure motifs, compared to coumarin-type photoactive chromophores.
- T g glass transition temperatures
- Polymers used in intraocular lens manufacturing have preferably relative high refractive indices, which enable the fabrication of thinner intraocular lenses.
- the polymer used in an intraocular lens will have a refractive index greater than about 1.5 and presently most preferably greater than about 1.55.
- a linear or branched alkyl group having 1 to 10 C atoms denotes an alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, for example methyl, ethyl, iso -propyl, n -propyl, iso -butyl, n -butyl, tert -butyl, n -pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, n -hexyl, n- heptyl, n -octyl, ethylhexyl, n -nonyl or n -decyl.
- a linear or branched alkyl group having 1 to 20 C atoms include all examples for a linear or branched alkyl group having 1 to 10 C atoms including any alkyl group having 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 C atoms such as n -undecyl, n -dodecyl, n- tridecyl, n -tetradecyl, n -pentadecyl, n -hexadecyl, n -heptadecyl, n -octadecyl, n -nonadecyl and n -eicosyl.
- partially halogenated alkyl group denotes that at least one H atom of the alkyl group is replaced by F, Cl, Br or I.
- the alkyl group is partially fluorinated meaning that at least one H atom of the alkyl group is replaced by F.
- completely halogenated alkyl group denotes that all H atoms of the alkyl group are replaced by F, Cl, Br and/or I.
- the alkyl group is completely fluorinated meaning that all H atoms of the alkyl group are replaced by F.
- a preferred completely fluorinated alkyl group is trifluoromethyl.
- halogenated or preferably fluorinated corresponds additionally to other groups such as a halogenated cycloalkyl group, a halogenated alkoxy group or a halogenated thioalkyl group.
- a cycloalkyl group having 3 to 6 C atoms includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl which may be partially or completely halogenated or fluorinated as explained before.
- a linear or branched alkoxy group having 1 to 20 C atoms denotes an O-alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example methoxy, ethoxy, iso -propoxy, n- propoxy, iso -butoxy, n -butoxy, tert-butoxy, n -pentyloxy, 1-, 2- or 3-methylbutyloxy, 1,1-, 1,2- or 2,2-dimethylpropoxy, 1-ethylpropoxy, n- hexyloxy, n -heptyloxy, n -octyloxy, ethylhexyloxy, n -nonyloxy, n -decyloxy, n- undecyloxy, n -dodecyloxy, n -tridecyloxy, n -tetradecyloxy, n -
- a linear or branched thioalkyl group having 1 to 20 C atoms denotes a S-alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example thiomethyl, 1-thioethyl, 1-thio- iso -propyl, 1-thio- n -propoyl, 1-thio- iso -butyl, 1-thio- n -butyl, 1-thio- tert -butyl, 1-thio- n- pentyl, 1-thio-1-, -2- or -3-methylbutyl, 1-thio-1,1-, -1,2- or -2,2-dimethylpropyl, 1-thio-1-ethylpropyl, 1-thio- n -hexyl, 1-thio- n -heptyl, 1-thio- n- octyl, 1-thio-ethylhexy
- Preferred alkyl and alkoxy radicals have 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms.
- a polymerizable group is a group which can be subject to or can undergo polymerization thus forming an oligomer or a polymer.
- Polymerization is the process of taking individual monomers and chaining them together to make longer units. These longer units are called polymers.
- the compounds of formula (I) as described before and preferably described below are suitable monomers.
- the polymerizable group R 1 once oligomerized or polymerized thus forms or is part of the backbone of the oligomer or polymer comprising polymerized compounds of formula (I).
- Suitable polymerizable groups contain at least one double bond or at least one triple bond thus forming polymers where the linking is formed via carbon-carbon bonds.
- a suitable polymerizable group may contain silicon thus forming polysiloxanes or polysilazanes.
- the suitable polymerizable groups are selected from the group consisting of an alkenyl group of formula (5), wherein
- a preferred polymerizable group is selected from the group consisting of trimethoxysilyl, triethoxysilyl, diethoxymethylsilyl and the alkenyl group of formula (5) as described before and preferably described below.
- Aryl with 6 to 14 C atoms is an aryl group preferably selected from the group consisting of phenyl, naphthyl or anthryl, particularly preferably phenyl.
- linker -[B]- are therefore selected from the group of formulae (B-1) to (B-34), wherein R' and R 0 have a meaning as described before or preferably described below.
- the invention therefore relates additionally to compounds of formula (I) as described before wherein -[B]- corresponds to formula (1) and (2) and X 1 , X 2 , X 3 and X 4 have a meaning as described before.
- linker -[B]- corresponds to formula (1) or (2) and X 1 , X 3 and X 4 are CR' and R' has at each occurrence independently a meaning as described before or preferably described below. Therefore, compounds of formula (I) are particularly preferred where the linker -[B]- corresponds to formulae (B-1), (B-3), (B-8) or (B-9).
- the invention therefore relates additionally to compounds of formula (I) as described before wherein -[B]- corresponds to formula (1) and (2) and X 1 , X 3 and X 4 are CR' and R' has at each occurrence independently a meaning as described before or preferably described below.
- the invention therefore relates additionally to compounds of formula (I) as described or preferably described before wherein -[B]- corresponds to formula (1) and (2) and X 2 is CR' and R' has at each occurrence independently a meaning as described before or preferably described below.
- R' is at each occurrence independently selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a linear or branched hydroxyalkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms.
- At least one R' in -[B]- as described before or preferably described before is different from H and is selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, a linear or branched hydroxyalkyl group having 1 to 20 C atoms, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms.
- At least two R' are different from H and are independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a linear or branched hydroxyalkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms.
- R' is at each occurrence independently preferably selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.
- At least one R' in -[B]- as described before or preferably described before is different from H and is selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.
- At least two R' are different from H and are independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.
- R' is at each occurrence independently particularly preferably selected from the group consisting of H, F, methyl, ethyl, n -propyl, n -butyl, n -pentyl, n- hexyl, n -heptyl, n -octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy and pentafluoroethoxy.
- R' is at each occurrence independently very particularly preferably selected from the group consisting of H, F, ethyl, n -pentyl, trifluoromethyl, methoxy, and trifluoromethoxy.
- the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (1) to (4) and wherein at least one R' within X 1 , X 2 , X 3 . X 4 , X 6 or X 7 is not H.
- the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1) to (B-29) or (B-31) to (B-34) or to preferred linkers as described before, wherein at least one R' is not H and R 0 has a meaning as described before or preferably described below.
- the substituent R' within X 1 or X 3 in formula (1) is particularly preferred not H.
- the substituent R' within X 7 in formula (3) is particularly preferred not H.
- R 3 , R 4 , R 5 and R 6 are at each occurrence independently R' where R' has a meaning or a preferred or particularly preferred meaning as described before.
- R 5 is preferably H or F.
- R 5 is particularly preferably H.
- R 7 corresponds to R' in case m is 0 wherein R' has a meaning or a preferred or particularly preferred meaning as described before.
- R 7 corresponds to R' which is not H in case m is 0.
- R' is preferably not H, it is selected from the preferred group consisting of F, methyl, ethyl, n -propyl, n -butyl, n -pentyl, n -hexyl, n- heptyl, n -octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy and pentafluoroethoxy or from the particular preferred group consisting of F, ethyl, n -pentyl, trifluoromethyl, methoxy and trifluoromethoxy.
- the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (1) to (4) and wherein at least one R' within X 1 , X 2 , X 3 . X 4 , X 6 or X 7 is not H and R 7 is not H in case m is 0.
- the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1) to (B-29) or (B-31) to (B-34) or to preferred linkers as described before, wherein at least one R' is not H and R 7 is not H in case m is 0 and R 0 has a meaning as described before or as preferably described below.
- the substituent R 7 corresponds to R 1 in case m is 1 wherein R 1 has a meaning or a preferred meaning as described before or further below.
- Compounds of formula (I) in which m is 1 are preferred having a linker -[B]- selected from the group consisting of formula (1) to (4) wherein at least one substituent R' within X 1 , X 2 , X 3 , X 4 , X 6 or X 7 is not H and in which at least one substituent R 3 , R 4 or R 6 is not H.
- the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (1) to (4) and wherein at least one R' within X 1 , X 2 , X 3 . X 4 , X 6 or X 7 is not H, in which at least one substituent R 3 , R 4 or R 6 is not H and R 7 corresponds to R 1 in case m is 1.
- the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1) to (B-29) or (B-31) to (B-34) or to preferred linkers as described before, wherein at least one R' is not H, in which at least one substituent R 3 , R 4 or R 6 is not H and R 7 corresponds to R 1 in case m is 1 wherein R 0 and R 1 has a meaning as described before or further below.
- R 0 is at each occurrence independently preferably methyl, ethyl, iso -propyl, 2-methyl-propyl, n -butyl, n -pentyl, 4-methyl-pentyl or cyclopropyl.
- R 0 is particularly preferably ethyl, iso -propyl, 2-methyl-propyl, n -pentyl or 4-methyl-pentyl.
- R 0 is particularly preferably methyl or n -butyl.
- R 0 is particularly preferably methyl.
- the compounds of formula (I) as described before or preferably described before contain one polymerizable group R 1 .
- R 1 polymerizable group
- Such compounds can be preferably used as monomers for the preparation of a blank which may be transformed to an ophthalmic device such as an eye-implant or specifically an intraocular lens or to the ophthalmic device as such as described before.
- the invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m is 0 which can preferably be described according to formula (I') wherein R 1 , -R 2 -, Y, R 3 , R 4 , R 5 , R 6 , X, -[B]- and R 7 have a meaning as described before or preferably described before or below.
- the invention is therefore additionally directed to compounds of formula (I) wherein n is 0 and m is 1 which can preferably be described according to formula (I") wherein R 1 , -R 2 -, Y, R 3 , R 4 , R 5 , R 6 , X, -[B]- and R 7 have a meaning as described before or preferably described before or below.
- the compounds of formula (I) as described before or preferably described before contain two polymerizable groups R 1 .
- R 1 polymerizable groups
- Such compounds can be preferably used as cross-linking agent for the preparation of a blank which may be transformed to an ophthalmic device such as an eye-implant or specifically an intraocular lens or to the ophthalmic device as such as described before.
- the invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m is 1 which can preferably be described according to formula (I'") wherein R 1 , -R 2 -, Y, R 3 , R 4 , R 5 , R 6 , X, -[B]- and R 7 have a meaning as described before or preferably described before or below.
- Y is at each occurrence independently O, S or a bond.
- the linking element -R 2 - is selected from the group consisting of -(C(R) 2 ) o -wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms, -(C(R) 2 ) p -X 8 -(C(R) 2 ) q -(X 9 ) s -(C(R) 2 ) r -(X 10 ) t -(C(R) 2 ) u -, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o is
- the linking element -R 2 - is selected from the group consisting of -(C(R) 2 ) o - wherein at least two R are F, -(C(R) 2 ) p -X 8 -(C(R) 2 ) q -(X 9 ) s -(C(R) 2 ) r -(X 10 ) t -(C(R) 2 ) u -, wherein at least two R are F and a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o, X 8 , X 9 , X 10 , s, t, p, q, r and u have a meaning as described or preferably described before or below.
- R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 8 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms.
- R is preferably at each occurrence independently selected from the group consisting of H, F, methyl, ethyl, n -propyl, isopropyl, n -butyl, n -pentyl, isobutyl, ethylhexyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl and nonafluorobutyl.
- R is particularly preferably at each occurrence independently H, F, methyl, 2,2,2-trifluoroethyl or trifluoromethyl.
- o is selected from the group consisting of 3 to 12, particularly preferably 8 to 12.
- s is 1.
- t is 0 or 1.
- X 8 , X 9 and X 10 are O.
- p and u are each independently 1, 3, 3, 4, 5 or 6, particularly preferably 1 or 2.
- q and r are each independently 1, 2 or 3, particularly preferably 1.
- Suitable examples for -R 2 - are -(CF 2 )-(CH 2 )-, -(CH 2 )-(CF 2 )-, -(CH 2 )-(CF 2 )-(CH 2 )-, -(CH 2 )-(CF 2 )-(CH 2 ) 2 -, - (CH 2 )-(CF 2 )-(CH 2 ) 3 -, -(CH 2 )-(CF 2 )-(CH 2 ) 4 -, -(CH 2 )-(CF 2 )-(CH 2 ) 5 -, -(CH 2 )-(CF 2 )-(CH 2 ) 6 -, -(CH 2 )-(CF 2 )-(CH 2 ) 7 -, -(CH 2 )-(CF 2 )-(CH 2 ) 8 -, -(CH 2 )-(CF 2 )-(CH 2 ) 9 -, -(CH 2 )-
- Preferred examples for -R 2 - are -(CH 2 ) 3 -(CF 2 )-(CH 2 ) 3 -, -(CH 2 )-(CF 2 ) 3 -(CH 2 )-, -(CH 2 ) 2 -(CF 2 ) 4 -(CH 2 ) 2 -, -(CH 2 )-[CH(CF 3 )]-(CH 2 )-, -(CH 2 )-[C(CH 3 )CF 3 ]-(CH 2 )-, -(CH 2 )-[CH(CH 2 CF 3 )]-(CH 2 )-, -(CH 2 )-[C(CH 3 )(CH 2 CF 3 )]-(CH 2 )-, -(CH 2 ) 2 -(CF 2 )-O-(CF 2 )-O-(CF 2 )-(CH 2 ) 2 -, -(CH 2 )-(CF 2 )-O-(
- the invention therefore relates to compounds of formula (I), (I'), (I") and (I''') as described before or preferably described before wherein -R 2 - is at each occurrence independently -(C(R) 2 ) o -, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R) 2 ) p -X 8 -(C(R) 2 ) q -(X 9 ) s -(C(R) 2 ) r -(X io ) t -(C(R) 2 ) u -, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and all other R, o, X 8 , X 9 , X 10 , s, t, p, q, r and u have a meaning as
- the linking element -(C(R) 2 ) o - or -(C(R) 2 ) p -X 8 -(C(R) 2 ) q -(X 9 ) s -(C(R) 2 ) r -(X 10 )t-(C(R) 2 ) u - as -R 2 - is particularly preferably selected from the group consisting of -(CH 2 ) 3 -(CF 2 )-(CH 2 ) 3 -, -(CH 2 )-(CF 2 ) 3 -(CH 2 )-, -(CH2)2-(CF2)4-(CH 2 ) 2 -, -(CH 2 )-[CH(CF 3 )]-(CH 2 )-, -(CH 2 )-[C(CH 3 )CF 3 ]-(CH 2 )-, -(CH 2 )-[CH(CH 2 CF 3 )]-(CH 2 )-, -
- the substituent Y-R 2 -R 1 is particularly preferably selected from the group consisting of O-R 2 -R 1 , -R 2 -R 1 , and S-R 2 -R 1 wherein -R 2 - has a meaning as described before or preferably or particularly preferably described before and wherein R 1 is a polymerizable group selected from the group consisting of a trialkoxysilyl group, a dialkoxyalkylsilyl group, a silyl group of formula (6), (7) or (8) as described before where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or an alkenyl group of formula (5), wherein
- the substituent Y-R 2 -R 1 is preferably selected from the group consisting of O-R 2 -R 1 , -R 2 -R 1 and S-R 2 -R 1 , wherein -R 2 - is selected from the group consisting of -(CH 2 ) 3 -(CF 2 )-(CH 2 ) 3 -, -(CH 2 )-(CF 2 ) 3 -(CH 2 )-, -(CH 2 ) 2 -(CF 2 ) 4 -(CH 2 ) 2 -, -(CH 2 )-[CH(CF 3 )]-(CH 2 )-, -(CH 2 )-[C(CH 3 )CF 3 ]-(CH 2 )-, -(CH 2 )-[CH(CH 2 CF 3 )]-(CH 2 )-, -(CH 2 )-[C(CH 3 )(CH 2 )-, -(CH 2 )-[CH(CH
- R 9 and R 10 are H.
- R 8 is H, methyl, ethyl or phenyl.
- Preferred alkenyl groups of formula (5) are therefore represented by any one selected from the group consisting of formulae (5-1), (5-2), (5-3), (5-4), (5-5), (5-6), (5-7), (5-8), and (5-9):
- the alkenyl group represented by formula (5-1) is called methacrylate.
- the alkenyl group represented by formula (5-2) is called acrylate.
- the preferred groups R 1 are preferably combined with preferred groups of the linking element -R 2 - and/or the linking element Y-R 2 -. Combinations are excluded where two O atoms or one O atom and one S atom are directly bonded to each other as known for a skilled artisan in the field of organic chemistry.
- the substituent Y-R 2 -R 1 is therefore particularly preferably selected from the group consisting of O-(CH 2 ) 3 -(CF 2 )-(CH 2 ) 3 -R 1 , O-(CH 2 )-(CF 2 ) 3 -(CH 2 )-R 1 , O-(CH 2 ) 2 -(CF 2 ) 4 -(CH 2 ) 2 -R 1 , O-(CH 2 )-[CH(CF 3 )]-(CH 2 )-R 1 , O-(CH 2 )-[C(CH 3 )CF 3 ]-(CH 2 )-R 1 , O-(CH 2 )-[CH(CH 2 CF 3 )]-(CH 2 )-R 1 , O-(CH 2 )-[C(CH 3 )(CH 2 CF 3 )]-(CH 2 )-R 1 , O-(CH 2 )-[C(CH 3 )(CH 2 CF 3 )]
- the compounds of formula (I), (I'), (I") and (I''') comprise a polymerizable group R 1 which is a methacryl or an acryl group represented by formula (5-1) and (5-2).
- the invention therefore relates further to compounds of formula (I), (I'), (I") and/or (I''') as described before or preferably described before wherein R 1 is at each occurrence independently an acryl or methacryl group.
- Examples for compounds of formula (I), (I'), (I") and/or (I''') are the following compounds O-001 to 0-289, S-001 to S-169 and N-001 to N-172:
- the compounds of the present application may be synthesized by methods well known to the skilled person. Preferably, all syntheses are carried out under an inert atmosphere using dried solvents.
- the first type of reaction is a classic aldol-addition with subsequent decarboxylation.
- the second type of reaction is a Palladium catalyzed Suzuki reaction.
- the third type of reaction is an ether cleavage in the presence of borontribromide.
- the fourth type of reaction is a Williamson ether synthesis.
- the fifth type of reaction is an esterification reaction.
- the first type of reaction is a classical ring closure via nucleophilic substitution, aldol-addition followed by decarboxylation.
- a pentyl substituent is introduced via palladium-catalyzed Suzuki reaction.
- the third type of reaction is an ether cleavage in the presence of borontribromide.
- the fourth type of reaction is a Williamson ether synthesis followed by an esterification reaction.
- the first type of reaction is a Sonogashira reaction followed by a ring closure in the presence of Zinc bromide.
- an alkyl group on the N atom is introduced via alkyl iodide.
- the third type of reaction is an ether cleavage in the presence of borontribromide.
- the fourth type of reaction is a Williamson ether synthesis followed by an esterification reaction.
- the compounds of formula (I), (I'), (I") and/or (I''') as described before or preferably described before contain a polymerizable group and are predestinated as monomers for an oligomerization or a polymerization.
- the invention is therefore further directed to an oligomer or polymer comprising polymerized compounds of formula (I), (I'), (I") and/or (I''') as described before or preferably described before.
- polymer generally means a molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass ( PAC, 1996, 68, 2291 ).
- polymer includes homopolymers and co-polymers.
- oligomer generally means a molecule of intermediate relative molecular mass, the structure of which essentially comprises a small plurality of units derived, actually or conceptually, from molecules of lower relative molecular mass ( PAC, 1996, 68, 2291 ). In a preferred sense a polymer means a compound having ⁇ 30 repeating units, and an oligomer means a compound with > 1 and ⁇ 30 repeating units.
- an asterisk denotes a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group.
- Suitable terminal end groups are known to the skilled artisan and depend on the polymerization method used.
- repeating unit and “monomeric unit” mean the constitutional repeating unit (CRU), which is the smallest constitutional unit the repetition of which constitutes a regular macromolecule, a regular oligomer molecule, a regular block or a regular chain ( PAC, 1996, 68, 2291 ).
- CRU constitutional repeating unit
- the molecular weight is given as the number average molecular weight M n or weight average molecular weight Mw, which is determined by gel permeation chromatography (GPC) against polystyrene standards in eluent solvents such as tetrahydrofuran, trichloromethane (TCM, chloroform), chlorobenzene or 1,2,4-trichlorobenzene. Unless stated otherwise, tetrahydrofuran is used as solvent.
- the total number of repeating units n is seen preferably ⁇ 30, very preferably ⁇ 100, most preferably ⁇ 200, and preferably up to 5000, very preferably up to 3000, most preferably up to 2000, including any combination of the aforementioned lower and upper limits of n.
- the polymers of the present invention include homopolymers, statistical co-polymers, random co-polymers, alternating co-polymers and block co-polymers, and combinations of the aforementioned.
- the polymerizable group R 1 forms the regioregular, alternated, regiorandom, statistical, block or random homopolymer or co-polymer backbone or is part of the polymer backbone where R 1 has a meaning as described or preferably described before.
- such oligomer or polymer comprises a constitutional unit M 0 of formulae (5-p-1), (5-p-2), (5-p-3) wherein -R 2 -, Y, R 3 , R 4 , R 5 , R 6 , X, -[B]-, R 7 , X 11 , R 8 , R 9 , R 10 and c have a meaning or a preferred meaning as described or preferably described before.
- Combinations are excluded where two O atoms or an O atom and a S atom are directly linked to each other as known for a skilled artisan in the field of organic chemistry.
- the co-polymer may be an oligomer or polymer comprising one or more polymerized compounds of formula (I), (I'), (I") or (I''') or a constitutional unit M 0 of formulae (5-p-1), (5-p-2), (5-p-3), which may be the same or different from one another, and one or more constitutional units M 2 , which may be the same or different from one another. Said one or more constitutional units M 2 are chemically different from the units M 0 .
- said one or more constitutional units M 2 are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2-phenoxyethyl acrylate (
- said one or more constitutional units M 2 are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18
- said one or more constitutional units M 2 are derived by polymerization of one or more monomers selected from the group consisting of trialkoxyalkenylsilane, dialkoxyalkylalkenylsilane or a silane of formula (9) and (10), where the alkyl and/or alkoxy groups are at each occurrence independently of each other linear or branched having 1 to 6 C atoms and where the alkenyl group is at each occurrence independently linear having 2 to 4 C atoms in combination with inventive monomers containing a polymerizable group containing at least one Si atom.
- the oligomer or polymer according to the invention is a homopolymer, i.e. an oligomer or polymer comprising one or more constitutional unit M 0 of formulae (5-p-1), (5-p-2), (5-p-3), wherein all constitutional units M 0 are the same.
- Exemplary polymeric compounds may be selected from the following formulae (P-001) to (P-628):
- n gives the degree of polymerization as explained before.
- a co-polymer according to the invention as described before or preferably described before comprises the one or more constitutional units M 0 in a molar ratio m1 and the one or more constitutional units M 2 in a molar ratio m2, wherein the ratio m1 : m2 is at least 0.01 and at most 100.
- oligomers or polymers according to the invention as described before or preferably described may be cross-linked.
- the oligomers and polymers of the present invention may be made by any suitable method. It is, however, preferred that the present oligomers and polymers are made by radical polymerization, wherein the polymerization reaction is started by means of a suitable radical polymerization initiator.
- a suitable radical polymerization initiator is not particularly limited and may be any suitable radical generating compound. Such compounds are well known to the skilled person.
- Suitable polymerization initiators comprising one or more peroxide groups may, for example, be selected from the groups consisting of t-butyl(peroxy-2-ethyl-hexanoate), di-(tert-butylcyclohexyl)peroxydicarbonate and benzoyl peroxide.
- Suitable polymerization initiators comprising one or more azo groups may, for example, be selected from the group consisting of 1,1'-azobis(cyclohexancarbonitrile) and 2,2'azobis(cyclohexanecarbonitrile) (AIBN).
- a suitable example of a photoinitiator is dimethylaminobenzoate /camphorquinone.
- the wavelength required to decompose said photoinitiator is different from the wavelength needed to irradiate the compound of the present application so as to change its optical properties.
- the radical initiators are used in an amount of at least 0.0001 eq and of at most 0.1 eq of the main monomer.
- Such radical initiators could be thermal initiators, e.g. azobisisobutyronitrile (AIBN) or photochemical initiators like dimethylaminobenzoate/camphorquinone.
- the present invention is also directed to a composition
- a composition comprising at least one compound of formula (I), (I'), (I") or (I''') as described or preferably described before and/or an oligomer or polymer as described before or preferably described before.
- a composition comprising at least one compound of formula (I), (I'), (I") or (I''') as described or preferably described before and an oligomer or polymer as described before is primarily used for the synthesis of block co-polymers with the condition that the oligomer or polymer has at least one reactive group left which may react with the monomers.
- composition may comprise further different components.
- further components may, for example, be selected from the group consisting of UV absorbers, antioxidants and cross-linkers.
- compositions may include or comprise, essentially consist of or consist of the said requisite or optional constituents. All compounds or components which can be used in the compositions are either known and commercially available or can by synthesized by known processes.
- UV absorber that may be used in the present composition is not particularly limited and can easily be selected from those generally known to the skilled person.
- suitable UV absorbers are characterized by being unsaturated compounds, preferably compounds comprising one or more selected from group consisting of olefinic groups, aryl groups and heteroaryl groups; these groups may be present in any combination.
- Suitable UV-absorbers for use in the present composition may, for example, be selected from those comprising a group selected from benzotriazole, benzophenone and triazine.
- Suitable UV-absorbers are, for example, disclosed in U.S. Pat. Nos. 5,290,892 ; 5,331,073 and 5,693,095 .
- Suitable cross-linkers may be used to impart elastomeric properties to the present composition and the articles produced therewith.
- any suitable di- or tri-functional monomer may be used as crosslinker.
- Such monomers are generally well known to the skilled person including at least one compound of formula (I''') as described before or preferably described before.
- Preferred cross-linker may be selected from the following group of compounds Ethylene glycol dimethacrylate (EGDMA) is particularly preferred.
- EGDMA Ethylene glycol dimethacrylate
- Suitable antioxidants are phenyl acrylate derivatives bearing a hindered phenol moiety.
- a preferred antioxidant is
- the compounds of formula (I) according to the invention and their oligomers or polymers as described before or preferably described before are particularly well suited for use in optically active devices.
- the present invention is also directed to articles e.g. blanks which may be transformed into optically active devices comprising at least one compound of formula (I) as described before or preferably described before or at least one oligomer or polymer as described before or preferably described before.
- Preferred articles are blanks which may be transformed into optically active devices or the optically active devices as such.
- Preferred optically active devices are ophthalmic devices. Examples of such ophthalmic devices include lenses, keratoprostheses, and cornea inlays or rings. More preferably, said article is a blank which may be transformed into an eye-implant or the eye-implant as such. More preferably, said eye-implant is a lens. Most preferably, such article is a blank which may be transformed into an intraocular lens or the intraocular lens as such, which may, for example, be a posterior chamber intraocular lens or an anterior chamber intraocular lens.
- a blank of this invention may be produced as a step in the manufacturing process used to create an intraocular lens.
- a manufacturing process may include the steps of polymer synthesis, polymer sheet casting, blank cutting, optic lathe cutting, optic milling, haptic milling or attachment, polishing, solvent extraction, sterilization and packaging.
- present articles according to the invention as described before or preferably described before may be formed by a process comprising the steps of
- Intraocular lenses in accordance with the present invention are believed to show particularly advantageous properties in that they are flexible enough so as to be rolled or folded and consequently requiring a much smaller incision for them to be inserted into the eye. It is believed that this will allow for improved healing of the eye, particularly in respect to the time for the eye to heal.
- the type of intraocular lens is not limited in any way. It may, for example, comprise one or more optic and one or more haptic components, wherein the one or more optic components serve as lens and the one or more haptic components are attached to the one or more optic components and hold the one or more optic components in place in the eye.
- the present intraocular lens may be of a one-piece design or of multi-piece design, depending on whether the one or more optic components and the one or more haptic components are formed from a single piece of material (one-piece design) or are made separately and then combined (multi-piece design).
- the present intraocular lens is also designed in such a way that it allows to be, for example, rolled up or folded small enough so that it fits through an incision in the eye, said incision being as small as possible, for example, at most 3 mm in length.
- intraocular lenses in accordance with the present invention allow for the non-invasive adjustment of the optical properties, particularly the refractive power, after implantation of the lens into the eye, thus reducing the need for post-surgery vision aids or reducing or totally avoiding follow-up surgery.
- the present invention is also directed to a process of changing the optical properties of an article as defined or preferably defined herein, said process comprising the steps of
- said irradiation has a wavelength of at least 250 nm or 300 nm, more preferably of at least 350 nm, even more preferably of at least 400 nm, still even more preferably of at least 450 nm, and most preferably of at least 500 nm.
- said irradiation has a wavelength of at most 1400 nm or 1300 nm or 1200 nm or 1100 nm or 1000 nm, more preferably of at most 950 nm or 900 nm, even more preferably of at most 850 nm, still even more preferably of at most 800 nm and most preferably of at most 750 nm.
- DCM is used to denote dichloromethane.
- DMF is used to denote dimethylformamide.
- EE is used to denote ethyl acetate.
- THF is used to denote tetrahydrofuran.
- Co-polymer-properties can be investigated on blanks, prepared by bulk polymerization of the monomers. Co-monomers, cross-linkers and initiators therefore can be purchased from commercial sources. All chemicals are of highest purity available and can be used as received.
- GSP 1 General remarks & general synthetic procedures (GSP 1) for the reduction of aliphatic diesters or diketones to the corresponding diols:
- Solid, fine powdered lithiumaluminium hydride (2.0 - 5.0 equiv.) is suspended in dry THF at room temperature.
- the corresponding diacid- or diester derivative is dissolved in dry THF and the solution is slowly added dropwise to the lithiumaluminium slurry while cooling with an ice bath.
- the reaction solution is warmed to room temperature and the consumption of the starting material is checked by TLC.
- the suspension is carefully quenched with 2M H 2 SO 4 , additional water is added. For a better workup, the suspension should have a pH of ⁇ 7.
- the phases are separated and extracted with Et 2 O.
- the organic phase is washed with H 2 O, dried over MgSO 4 and evaporated under reduced pressure.
- GSP 4 General remarks & general synthetic procedures (GSP 4) for the synthesis of 2-phenyl-benzofurans from hydroxy-benzaldehyde derivatives or dimethyl-thiocarbamic acid 4-formyl-3-hydroxy-phenyl ester derivatives with methyl 2-bromo-2-(4-bromophenyl)acetate:
- R1 means reactant 1
- R2 means reactant 2
- [P] means product No. Yield [%] 4a R1 R2 [P] 39
- 4d R1 R2 [P] 69
- 4e R1 R2 [P] 62
- 4g R1 R2 [P] 57 4h R1 R2 [P] 49 4i R1 R2 [P] 44 4j R1 R2 [P] 52 4k R1 R2 [P] 32
- the cooled reaction mixture is diluted with ethyl acetate and HCI solution (2 M). The solution is transferred to a separatory funnel. The organic phase is extracted with HCI solution (2 M) and water and brine. The organic phase is dried over MgSO 4 , filtered and concentrated under reduced pressure. The residue is purified by silica gel column chromatography (heptane/ethyl acetate [5/1]) to yield 6-Methoxy-2-(4-pentyl-phenyl)-benzofuran (350 mg, 1.2 mmol, 66% of theory).
- R1 means reactant 1
- R2 means reactant 2
- [P] means product No. Yield [%] 5a R1 R2 [P] 75 5b R1 R2 [P] 80 5c R1 R2 [P] 72 5d R1 R2 [P] 73 5e R1 R2 [P] 92 5f R1 R2 [P] 60
- the obtained light brown oil is purified using silica gel chromatography (chloroform/methanol; 30/1) to afford 2-(2-ethyl-4-pentylphenyl)benzofuran-6-thiol (400.00 mg, 1.1 mmol, 53 % of theory).
- R1 means reactant 1
- R2 means reactant 2
- [P] means product No. 7a
- R1 R2 [P] 7g R1 R2 [P] 7h
- the bromo-functionalized derivatives of the corresponding diols are prepared in advance through reaction of the corresponding diol with HBr in refluxing toluene.
- 3,3,4,4,5,5,6,6-octafluoro-8-((2-(4-pentyl-2-(trifluoromethoxy)phenyl)benzofuran-6-yl)thio)octan-1-ol can be isolated in 76% yield (of theory) as a pale beige solid.
- the corresponding aliphatic alcohol is dissolved in dry THF and the solution is cooled with an ice-bath. Triethylamine (4.00 equivs.) is added and the solution is stirred for a few minutes. Then acryloyl chloride or methacryloyl chloride (1.05 - 2.00 equivs.) is added at ice-bath temperature, while precipitating a colourless solid. The solution is stirred for several hours and is monitored via TLC. Upon completion of the reaction, the suspension is filtrated and washed with THF. The filtrate is evaporated under reduced pressure and purified via column chromatography using cyclohexane / ethyl acetate.
- the corresponding monomer is dissolved in dry N,N-dimethylformamide in a Schlenck-tube with a stirring bar.
- the solution is degassed performing three times freeze-evacuate-thaw cycles.
- azoisobutyronitrile AIBN, 0.05 equiv.
- AIBN azoisobutyronitrile
- the solution is cooled to room temperature and is then poured dropwise into cold methanol (100 ml methanol / 100 mg monomer) while stirring.
- the precipitated polymer is collected on a frit or the solution is centrifuged several times to obtain the final polymer material.
- the cooled reaction mixture is diluted with ethyl acetate and HCI solution (2 M). The solution is transferred to a separatory funnel. The organic phase is extracted with HCI solution (2 M) and water and brine. The organic phase is dried over MgSO 4 , filtered and concentrated under reduced pressure. The residue is purified by silica gel column chromatography (heptane/ethyl acetate [5/1]) to yield 6-methoxy-2-(4-pentylphenyl)benzo[b]thiophene (390 mg, 1.26 mmol, 84 % of theory).
- 6-Methoxy-2-phenyl-benzo[b]thiophene (780.00 mg, 3.25 mmol) is dissolved in Dichloromethane (anhydrous) (20.73 ml, 324.57 mmol) and cooled to 5 °C.
- Boron tribromide (369.60 ⁇ l, 3.89 mmol) is added dropwise to this solution over the course of 10 min, and stirring is continued for 2 h.
- the reaction mixture is subsequently slowly poured into water, and the organic phase is diluted with ethyl acetate, washed three times with water, dried over MgSO 4 , evaporated in a rotary evaporator.
- R means reactant
- [P] means product No. Yield [%] 13a
- R1 means reactant 1
- R2 means reactant 2
- [P] means product No. 14a R1 R2 [P] 14b R1 R2 [P] 14c R1 R2 [P] 14d R1 R2 [P] 14e R1 R2 [P] 14f R1 R2 [P] 14g R1 R2 [P] 14h R1 R2 [P]
- the corresponding aliphatic alcohol is dissolved in dry THF and the solution is cooled with an ice-bath. Triethylamine (4.00 equivs.) is added and the solution is stirred for a few minutes. Then acryloyl chloride or methacryloyl chloride (1.05 - 2.00 equivs.) is added at ice-bath temperature, while precipitating a colourless solid. The solution is stirred for several hours and is monitored via TLC. Upon completion of the reaction, the suspension is filtrated and washed with THF. The filtrate is evaporated under reduced pressure and purified via column chromatography using cyclohexane / ethyl acetate.
- R means reactant
- [P] means product No. 15a
- 15f R [P] 15g
- the corresponding monomer is dissolved in dry N,N-dimethylformamide in a Schlenck-tube with a stirring bar.
- the solution is degassed performing three times freeze-evacuate-thaw cycles.
- azoisobutyronitrile AIBN, 0.05 equiv.
- AIBN azoisobutyronitrile
- the solution is cooled to room temperature and is then poured dropwise into cold methanol (100 ml methanol / 100 mg monomer) while stirring.
- the precipitated polymer is collected on a frit or the solution is centrifuged several times to obtain the final polymer material.
- R1 means reactant 1
- R2 means reactant 2
- [P] means product No. Yield [%] 19a
- 19b means reactant 2
- [P] means product No. Yield [%] 19a
- 19b means reactant 2
- [P] means product No. Yield [%] 19a
- 19b 19b
- 19c means R1 R2 [P] 74
- R1 R2 [P] 85 19e
- 6-Methoxy-1-methyl-2-phenylindole (184 mg, 775 ⁇ mol) is dissolved in dichloromethane (10 ml) and cooled to 5 °C. Boron tribromide (96.6 ⁇ l, 1.0 mmol) are added dropwise to this solution, and stirring is continued overnight. Water is subsequently slowly added to the mixture, and the organic phase is diluted with ethyl acetate, washed three times with water, dried over MgSO 4 , evaporated under reduced pressure and filtered through a pad of silica gel with dichloromethane to yield 6-hydroxy-1-methyl-2-phenylindole (117 mg, 524 ⁇ mol, 68 % of theory).
- R1 means reactant 1
- R2 means reactant 2
- [P] means product No. 21a R1 R2 [P] 21b R1 R2 [P] 21c R1 R2 [P] 21d R1 R2 [P] 21e R1 R2 [P] 21f R1 R2 [P] 21g R1 R2 [P] 21h R1 R2 [P] 21i R1 R2 [P] 21j R1 R2 [P] 21k R1 R2 [P] 21l R1 R2 [P]
- the corresponding aliphatic alcohol is dissolved in dry THF and the solution is cooled with an ice-bath. Triethylamine (4.00 equivs.) is added and the solution is stirred for a few minutes. Then acryloyl chloride or methacryloyl chloride (1.05 - 2.00 equivs.) is added at ice-bath temperature, while precipitating a colourless solid. The solution is stirred for several hours and is monitored via TLC. Upon completion of the reaction, the suspension is filtrated and washed with THF. The filtrate is evaporated under reduced pressure and purified via column chromatography using cyclohexane / ethyl acetate.
- R means reactant
- [P] means product No. 22a
- [P] 22b R [P] 22c
- [P] 22d R [P] 22e
- 22f R [P] 22g
- [P] R means reactant
- the corresponding monomer is dissolved in dry N,N-dimethylformamide in a Schlenck-tube with a stirring bar.
- the solution is degassed performing three times freeze-evacuate-thaw cycles.
- azoisobutyronitrile AIBN, 0.05 equiv.
- AIBN azoisobutyronitrile
- the solution is cooled to room temperature and is then poured dropwise into cold methanol (100 ml methanol / 100 mg monomer) while stirring.
- the precipitated polymer is collected on a frit or the solution is centrifuged several times to obtain the final polymer material.
- a composition of 1 H-indol derivative M-N3 and methyl methacrylate, initiator azobisisobutyronitrile (0.04 eq) and crosslinker ethylene glycol dimethacrylate (0.1 - 0.4 eq) in different ratios is degassed by three freeze-pump-thaw cycles.
- Two glass plates are coated with a polyethylene sheet and a 0.5 mm thick cell is created between the polyethylene sheets using a silicone rubber gasket.
- the coated faces of the glass sheets are clipped together using spring clips with a syringe needle being placed between the gasket and the polyethylene sheets.
- the cavity is then filled with the above formulation through the needle using a gastight syringe. Once the cavity is filled the syringe needle is removed, a final clip is used to seal the mould and the assembly is placed in an oven at 60°C for 24 hours before the oven is ramped to a temperature of 90°C for a period of 3 hours.
- the moulds are allowed to cool to room temperature before the film is removed from the mould.
- Example 25 photoinduced refractive index change and glass transition temperature
- phase transition temperatures are determined with a TA Instruments Q2000 differential scanning calorimeter during heating in the second heating run with 20 K/min from -100 °C to 200 °C in a hermetic aluminum pans. Irradiations of the blanks are performed with a Coherent Avia 355-7000 UV-Laser. Common photoactive polymers that undergo refractive index change upon irradiation with UV-light exhibit glass transition temperatures as low as 34°C.
- Polymer films for refractive index measurements are prepared by spin coating or drop casting from 1-8 wt% solutions of the polymers in chloroform onto silicon wafers or quartz plates.
- the monomers are melted under vacuum.
- Appropriate amounts of a radical initiator and cross-linker are mixed in and quickly filled into a heated polymerization chamber.
- Cross-linked polymer plates are obtained.
- Refractive index change is induced by irradiation at 340 - 365 nm.
- the refractive indices (n) of the polymer films and blanks at 590 nm are measured on Schmidt+Haensch AR12 before and after irradiation.
- the following table shows the refractive indices before and after irradiation as well as the change in refractive index (max. ⁇ n).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Materials For Medical Uses (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Claims (16)
- Composés de formule (I)X est O, S ou NR0,Y est indépendamment les uns des autres O, S ou une liaison,n vaut 0 ou 1,m vaut 0 ou 1,n+m vaut 1 ou 2,X1, X2, X3, X4 sont chacun indépendamment les uns des autres CR' ou N,X5 est chacun indépendamment O, S, C=O ou NR0,X6, X7 sont chacun indépendamment CR' ou N,R est choisi indépendamment à chaque occurrence dans le groupe constitué par H, F, un groupement alkyle linéaire ou ramifié ayant de 1 à 8 atomes de C ou un groupement alkyle linéaire ou ramifié partiellement ou totalement fluoré ayant de 1 à 4 atomes de C,R' est choisi indépendamment à chaque occurrence dans le groupe constitué par H, F, un groupement alkyle linéaire ou ramifié, non halogéné, partiellement ou totalement halogéné ayant de 1 à 20 atomes de C, un groupement hydroxyalkyle linéaire ou ramifié ayant de 1 à 20 atomes de C, un groupement cycloalkyle non halogéné, partiellement ou totalement halogéné ayant de 3 à 6 atomes de C, un groupement alcoxy linéaire ou ramifié, non halogéné, partiellement ou totalement halogéné ayant de 1 à 20 atomes de C, un groupement thioalkyle linéaire ou ramifié, non halogéné, partiellement ou totalement halogéné ayant de 1 à 20 atomes de C,R0 est choisi indépendamment à chaque occurrence dans le groupe constitué par un groupement alkyle linéaire ou ramifié ayant de 1 à 10 atomes de C ou un groupement cycloalkyle ayant de 3 à 6 atomes de C,R1 est un groupement polymérisable choisi dans le groupe constitué par
un groupement alcényle de formule (5),X10 est choisi dans le groupe constitué par O, S, C(=O), C(=O)O,R5, R9, R10 sont choisis à chaque occurrence, indépendamment les uns des autres, dans le groupe constitué par H, F, un groupement alkyle linéaire ou ramifié, non fluoré, partiellement ou totalement fluoré ayant de 1 à 20 atomes de C ou aryle ayant de 6 à 14 atomes de C,c vaut 0 ou 1 ; et des groupements trialcoxysilyle ou dialcoxyalkylsilyle où les groupements alkyle et/ou alcoxy sont chacun indépendamment linéaires ou ramifiés ayant de 1 à 6 atomes de C ; etdes groupements silyle de formule (6), (7) ou (8),-R2- est -(C(R)2)o- ou -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, où au moins un R est F ou un groupement alkyle linéaire ou ramifié partiellement ou totalement fluoré ayant de 1 à 4 atomes de C,
ou
un groupement cycloalkylène ayant 5 ou 6 atomes de C qui est substitué par au moins un R qui est F ou un groupement alkyle linéaire ou ramifié partiellement ou totalement fluoré ayant de 1 à 4 atomes de C,o est choisi dans le groupe constitué par de 1 à 20,X8, X9, X10 sont indépendamment à chaque occurrence O, S, ou NR0,s, t valent indépendamment à chaque occurrence 0 ou 1,p, q sont choisis indépendamment à chaque occurrence dans le groupe constitué par de 1 à 10,r, u sont choisis indépendamment à chaque occurrence dans le groupe constitué par de 0 à 10, où le nombre global d'atomes pour -(C(R)2)p-Xs-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, va jusqu'à 20 atomes,R3, R4, R5, R6 sont indépendamment à chaque occurrence R',R7 est R' dans le cas où m vaut 0 etR7 est R1 dans le cas où m vaut 1. - Composés selon la revendication 1, dans lesquels -[B]- correspond à la formule (1) ou la formule (2).
- Composés selon la revendication 1 ou 2, dans lesquels X1, X3 et X4 dans les formules (1) ou (2) sont CR' et R' revêt indépendamment à chaque occurrence une signification telle qu'indiquée selon la revendication 1.
- Composés selon l'une ou plusieurs parmi les revendications 1 à 3, dans lesquels X2 est CR' et R' revêt une signification telle qu'indiquée selon la revendication 1.
- Composés selon l'une ou plusieurs parmi les revendications 1 à 4, dans lesquels au moins un R' au sein de X1, X2, X3, X4, X6, ou X7 dans les formules (1) à (4) n'est pas H.
- Composés selon l'une ou plusieurs parmi les revendications 1 à 8, dans lesquels -R2- est indépendamment à chaque occurrence -(C(R)2)o- ou -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, où au moins un R est F ou un groupement alkyle linéaire ou ramifié partiellement ou totalement fluoré ayant de 1 à 4 atomes de C et tous les autres R, o, X8, X9, X10, s, t, p, q, r, et u revêtent une signification telle qu'indiquée selon la revendication 1.
- Composés selon l'une ou plusieurs parmi les revendications 1 à 9, dans lesquels R1 est indépendamment à chaque occurrence un radical acryle ou méthacryle.
- Oligomère ou polymère, comprenant des composés polymérisés de formule (I) tels que décrits selon l'une ou plusieurs parmi les revendications 1 à 10.
- Composition, comprenant au moins un composé de formule (I) selon l'une ou plusieurs parmi les revendications 1 à 10 et/ou un oligomère ou polymère selon la revendication 11.
- Article comprenant au moins un composé polymérisé de formule (I) selon l'une ou plusieurs parmi les revendications 1 à 10 ou au moins un oligomère ou polymère selon la revendication 11.
- Article selon la revendication 13, ledit article étant une ébauche qui peut être transformée en un implant oculaire ou un implant oculaire, préférablement une lentille intraoculaire.
- Procédé de façonnage d'un article selon la revendication 13 ou 14, ledit procédé comprenant les étapes consistant à- mettre à disposition une composition comprenant au moins un composé de formule (I) selon l'une ou plusieurs parmi les revendications 1 à 10 et/ou un oligomère ou polymère selon la revendication 11 ;- façonner ensuite l'article de ladite composition.
- Procédé de modification des propriétés optiques d'un article selon la revendication 13 ou 14, ledit procédé comprenant les étapes consistant à- mettre à disposition un article selon la revendication 13 ou 14, et- exposer ensuite ledit article à un rayonnement ayant une longueur d'onde d'au moins 200 nm et d'au plus 1500 nm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL18703798T PL3583091T3 (pl) | 2017-02-15 | 2018-02-14 | Związki hydrofobowe dla urządzeń aktywnych optycznie |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17156329.9A EP3363787A1 (fr) | 2017-02-15 | 2017-02-15 | Composés de dispositifs optiquement actifs |
PCT/EP2018/053625 WO2018149852A1 (fr) | 2017-02-15 | 2018-02-14 | Composés hydrophobes pour dispositifs optiquement actifs |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3583091A1 EP3583091A1 (fr) | 2019-12-25 |
EP3583091B1 true EP3583091B1 (fr) | 2020-11-04 |
Family
ID=58212900
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17156329.9A Ceased EP3363787A1 (fr) | 2017-02-15 | 2017-02-15 | Composés de dispositifs optiquement actifs |
EP18703798.1A Active EP3583091B1 (fr) | 2017-02-15 | 2018-02-14 | Composés de dispositifs optiquement actifs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17156329.9A Ceased EP3363787A1 (fr) | 2017-02-15 | 2017-02-15 | Composés de dispositifs optiquement actifs |
Country Status (7)
Country | Link |
---|---|
US (1) | US11014901B2 (fr) |
EP (2) | EP3363787A1 (fr) |
ES (1) | ES2850898T3 (fr) |
HU (1) | HUE052436T2 (fr) |
PL (1) | PL3583091T3 (fr) |
PT (1) | PT3583091T (fr) |
WO (1) | WO2018149852A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3133065A1 (fr) | 2015-08-21 | 2017-02-22 | Merck Patent GmbH | Composés de dispositifs optiquement actifs |
EP3363793A1 (fr) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Composés hydrophobes pour dispositifs optiquement actifs |
EP3363786A1 (fr) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Composés de dispositifs optiquement actifs |
EP3956334A1 (fr) | 2019-04-18 | 2022-02-23 | Merck Patent GmbH | Composés pour dispositifs optiquement actifs |
AU2020262316A1 (en) | 2019-04-26 | 2021-12-23 | AMO Ireland | System and method |
US20230203214A1 (en) | 2020-05-20 | 2023-06-29 | Merck Patent Gmbh | Azacoumarin and azathiocoumarin derivatives for use in optically active devices |
WO2022012798A1 (fr) | 2020-07-15 | 2022-01-20 | Merck Patent Gmbh | Dispositifs optiquement actifs |
EP4015512A1 (fr) | 2020-12-16 | 2022-06-22 | AMO Ireland | Dispositifs optiquement actifs |
EP4036085A1 (fr) | 2021-01-27 | 2022-08-03 | AMO Ireland | Composes pour dispositifs ophtalmiques optiquement actifs |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290892A (en) | 1990-11-07 | 1994-03-01 | Nestle S.A. | Flexible intraocular lenses made from high refractive index polymers |
US5331073A (en) | 1992-11-09 | 1994-07-19 | Allergan, Inc. | Polymeric compositions and intraocular lenses made from same |
CA2195092C (fr) | 1995-06-07 | 2002-07-09 | Charles Freeman | Materiaux ameliores pour lentilles ophtalmiques, a indice de refraction eleve |
DE102005045540A1 (de) | 2005-09-23 | 2007-03-29 | Hampp, Norbert, Prof. Dr. | Intraokularlinse |
DE102007059470B3 (de) * | 2007-12-11 | 2009-05-20 | *Acri.Tec Gmbh | Ophthalmologische Zusammensetzung und deren Verwendung |
WO2009074520A2 (fr) | 2007-12-11 | 2009-06-18 | *Acri.Tec Gmbh | Copolymère et composition ophtalmologique |
JP5654050B2 (ja) | 2010-02-04 | 2015-01-14 | エルジー・ケム・リミテッド | 新規のフッ素化化合物、これを含む組成物、これを利用した成形体、及び成形体の製造方法 |
EP3307798B2 (fr) | 2015-06-12 | 2024-06-05 | Transitions Optical, Inc. | Composés d'alignement |
EP3363786A1 (fr) * | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Composés de dispositifs optiquement actifs |
EP3363791A1 (fr) * | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Composés hydrophiles pour dispositifs optiquement actifs |
-
2017
- 2017-02-15 EP EP17156329.9A patent/EP3363787A1/fr not_active Ceased
-
2018
- 2018-02-14 WO PCT/EP2018/053625 patent/WO2018149852A1/fr unknown
- 2018-02-14 EP EP18703798.1A patent/EP3583091B1/fr active Active
- 2018-02-14 HU HUE18703798A patent/HUE052436T2/hu unknown
- 2018-02-14 US US16/485,844 patent/US11014901B2/en active Active
- 2018-02-14 ES ES18703798T patent/ES2850898T3/es active Active
- 2018-02-14 PL PL18703798T patent/PL3583091T3/pl unknown
- 2018-02-14 PT PT187037981T patent/PT3583091T/pt unknown
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
WO2018149852A1 (fr) | 2018-08-23 |
US20200055833A1 (en) | 2020-02-20 |
PT3583091T (pt) | 2021-02-03 |
US11014901B2 (en) | 2021-05-25 |
EP3583091A1 (fr) | 2019-12-25 |
ES2850898T3 (es) | 2021-09-01 |
HUE052436T2 (hu) | 2021-04-28 |
EP3363787A1 (fr) | 2018-08-22 |
PL3583091T3 (pl) | 2021-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3583091B1 (fr) | Composés de dispositifs optiquement actifs | |
US11014900B2 (en) | Hydrophilic compounds for optically active devices | |
US11753387B2 (en) | Compounds for optically active devices | |
EP3583102B1 (fr) | Composés hydrophobes pour dispositifs optiquement actifs | |
EP3583101B1 (fr) | Composés bis pour dispositifs optiquement actifs | |
EP3363792A1 (fr) | Composés contenant un atome de si pour des dispositifs optiquement actifs | |
CN113692407B (zh) | 用于光学活性器件的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190808 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200721 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1330646 Country of ref document: AT Kind code of ref document: T Effective date: 20201115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602018009445 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3583091 Country of ref document: PT Date of ref document: 20210203 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20210128 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E052436 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210204 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210304 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210204 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602018009445 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2850898 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210901 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
26N | No opposition filed |
Effective date: 20210805 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210214 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210214 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20211216 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20220109 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210304 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20220118 Year of fee payment: 5 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602018009445 Country of ref document: DE Owner name: AMO IRELAND, IE Free format text: FORMER OWNER: MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG, 64293 DARMSTADT, DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20220623 AND 20220629 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: GB9C Owner name: AMO IRELAND, IE Free format text: FORMER OWNER(S): MERCK PATENT GMBH, DE Ref country code: HU Ref legal event code: FH1C Free format text: FORMER REPRESENTATIVE(S): DANUBIA SZABADALMI ES JOGI IRODA KFT., HU Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: PD Owner name: AMO IRELAND; IE Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: MERCK PATENT GMBH Effective date: 20221004 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: AMO IRELAND; IE Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: MERCK PATENT GMBH Effective date: 20221121 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: PC Ref document number: 1330646 Country of ref document: AT Kind code of ref document: T Owner name: AMO IRELAND, IE Effective date: 20221122 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: AMO IRELAND Effective date: 20230619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230215 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231229 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240108 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 1330646 Country of ref document: AT Kind code of ref document: T Effective date: 20230214 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240306 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230214 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230214 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20231229 Year of fee payment: 7 Ref country code: PT Payment date: 20240212 Year of fee payment: 7 Ref country code: GB Payment date: 20240108 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20240209 Year of fee payment: 7 Ref country code: SE Payment date: 20240103 Year of fee payment: 7 Ref country code: PL Payment date: 20240115 Year of fee payment: 7 Ref country code: IT Payment date: 20240111 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |